Prof. Dr. Merih KIZIL ÇAKAR

1. Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial

Broome C. M., Miyakawa Y., McDonald V., Al-Samkari H., Khelif A., Cataland S. R., et al.

American Journal of Hematology , cilt.101, sa.7, ss.1494-1506, 2026 (SCI-Expanded, Scopus)

2. Impact of Dyslipidemia on Allogeneic Transplantation Outcomes and Cardiovascular Mortality in Patients with Acute Leukemias in the Post-Transplant Cyclophosphamide Era

Seçilmiş S., Aslan Candır B., Hatipoğlu U., Seyhan M., Uncu Ulu B., YİĞENOĞLU T. N., et al.

Pharmaceuticals , cilt.19, sa.4, 2026 (SCI-Expanded, Scopus)

3. Cladribine Treatment Outcomes in Hairy Cell Leukemia: A Single-center Experience

Seçilmiş S., Candır B. A., Yaman S., Bozan E., Ulu B. U., YİĞENOĞLU T. N., et al.

Acta Haematologica Oncologica Turcica , cilt.58, sa.3, ss.212-217, 2025 (Scopus, TRDizin)

4. Characteristics and Outcomes of Patients with Acute Promyelocytic Leukemia: A Single-center Experience

Seçilmiş S., Candır B. A., Bozan E., Yaman S., Ulu B. U., YİĞENOĞLU T. N., et al.

Acta Haematologica Oncologica Turcica , cilt.58, sa.2, ss.143-149, 2025 (Scopus, TRDizin)

5. Twice or once a day? Filgrastim dosing schedule for peripheral hematopoietic stem cells mobilization

Bakırtaş M., Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Kılınç A., Darçın T., et al.

Hematology, Transfusion and Cell Therapy , cilt.47, sa.1, 2025 (ESCI, Scopus)

6. Role of WT1 in Measurable Residual Disease Follow-Up in the Post Allogeneic Stem Cell Transplant Setting

NAMDAROĞLU S., BAŞCI S., Aslan Candır B., Yaman S., YİĞENOĞLU T. N., Bahsi T., et al.

Journal of Clinical Medicine , cilt.13, sa.17, 2024 (SCI-Expanded, Scopus)

7. Is an earlier strategy for harvesting peripheral blood stem cells in healthy allogeneic donors feasible?

Yaman S., Bozan E., Seçilmiş S., Candır B. A., Kılınç A., BAŞCI S., et al.

Transfusion and Apheresis Science , cilt.63, sa.4, 2024 (SCI-Expanded, Scopus)

8. Is neutropenic fever an obstacle to effective stem cell harvesting?

BAŞCI S., Bozan E., Yaman S., Ulu B. U., Bakırtaş M., YİĞENOĞLU T. N., et al.

Asian Journal of Transfusion Science , cilt.18, sa.1, ss.21-26, 2024 (ESCI, Scopus)

9. Is Ruxolitinib an Effective and Safe Therapy for Chronic Myeloproliferative Diseases? Ruksolitinib Kronik Miyeloproliferatif Hastalık için Etkili ve Güvenli Bir Tedavi mi?

Candır B. A., Seçilmiş S., Bozan E., Yaman S., YİĞENOĞLU T. N., KIZIL ÇAKAR M., et al.

Acta Haematologica Oncologica Turcica , cilt.57, sa.1, ss.1-7, 2024 (Scopus, TRDizin)

10. An effective treatment in Erdheim Chester disease: vemurafenib: a case report

Bozan E., Darçın T., Yaman S., YİĞENOĞLU T. N., KIZIL ÇAKAR M., DAL M. S., et al.

Journal of Medical Case Reports , cilt.17, sa.1, 2023 (ESCI, Scopus)

11. Latent tuberculosis in adult hematopoietic stem cell transplantation recipients: Clinical experience from a previously endemic population

MERT D., Ozer M., Merdin A., İSKENDER G., Uncu Ulu B., KIZIL ÇAKAR M., et al.

Medicine (United States) , cilt.101, sa.46, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities

Aslan Candır B., YİĞENOĞLU T. N., KIZIL ÇAKAR M., DAL M. S., ALTUNTAŞ F.

Journal of Oncology Pharmacy Practice , cilt.28, sa.4, ss.972-974, 2022 (SCI-Expanded, Scopus)

13. Could blood groups have prognostic significance on survival in patients with diffuse large B cell lymphoma?

Ulu B. U., BAŞCI S., Bakırtaş M., YİĞENOĞLU T. N., BATGİ H., YILDIZ J., et al.

Leukemia Research , cilt.115, 2022 (SCI-Expanded, Scopus)

14. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies

Yaman S., BAŞCI S., Turan G., Ulu B. U., YİĞENOĞLU T. N., DAL M. S., et al.

Clinical Lymphoma, Myeloma and Leukemia , cilt.22, sa.2, 2022 (SCI-Expanded, Scopus)

15. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

Uncu Ulu B., DAL M. S., Yönal Hindilerden İ., Akay O. M., MEHTAP Ö., BÜYÜKKURT N., et al.

Journal of Chemotherapy , cilt.34, sa.3, ss.190-198, 2022 (SCI-Expanded, Scopus)

16. Febrile neutropenia risk factors in actively treated diffuse large B-cell lymphoma patients

Bakirtas M., YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Yaman S., KIZIL ÇAKAR M., et al.

Iraqi Journal of Hematology , cilt.11, sa.1, ss.7-12, 2022 (Scopus)

17. Face masks and polycythemia is the standard hemoglobin cutoff valid in the pandemic?

Yaman S., BAŞCI S., Turan G., Ulu B. U., YİĞENOĞLU T. N., Bahsi T., et al.

Iraqi Journal of Hematology , cilt.11, sa.2, ss.130-133, 2022 (Scopus)

18. Efficiency of intravenous iron carboxymaltose in patients with iron-deficiency anemia due to heavy menstrual bleeding: a single-center experience

Seçilmiş S., İSKENDER D., Candir B., Bozan E., Yaman S., Ulu B., et al.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.10, ss.3487-3492, 2022 (SCI-Expanded, Scopus)

19. Pregnancy outcomes in female cancer survivors after hematopoietic stem cell transplantation

İSKENDER D., Ibanoǧlu M., Seçilmiş S., Baysal N., KIZIL ÇAKAR M., Dal M., et al.

European Review for Medical and Pharmacological Sciences , cilt.26, sa.3, ss.996-1003, 2022 (SCI-Expanded, Scopus)

20. Does myeloma genetic have an effect on stem cell mobilization?

BAŞCI S., YİĞENOĞLU T. N., Yaman S., Bozan E., Ulu B. U., Bakırtaş M., et al.

Transfusion and Apheresis Science , cilt.60, sa.6, 2021 (SCI-Expanded, Scopus)

21. Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma

Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Bakırtaş M., Şahin D., Darçın T., et al.

Leukemia Research , cilt.110, 2021 (SCI-Expanded, Scopus)

22. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with relapsed or refractory germ cell tumors

YILDIZ J., Ulu B. U., YİĞENOĞLU T. N., BAŞCI S., Bakirtas M., Sahin D., et al.

Journal of B.U.ON. , cilt.26, sa.6, ss.2531-2536, 2021 (SCI-Expanded, Scopus)

23. Molecular evaluation of mutations in acute myeloid leukemia patients from Turkey: A single-center study

Merdin A., DAL M. S., KIZIL ÇAKAR M., Bahsi T., Düzkale N., YILDIZ J., et al.

Medicine (United States) , cilt.100, sa.41, 2021 (SCI-Expanded, Scopus)

24. Efficacy and safety of plasmapheresis in symptomatic hyperviscosity and cast nephropathy: A Multicenter Experience in Turkey

Kalpakci Y., Hacibekiroglu T., Darcin T., AkgunCagliyan G., KIZIL ÇAKAR M., Hacioglu S. K., et al.

Transfusion and Apheresis Science , cilt.60, sa.5, 2021 (SCI-Expanded, Scopus)

25. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center

Secilmis S., DAL M. S., KIZIL ÇAKAR M., Merdin A., Baysal N. A., ALTUNTAŞ F.

Journal of B.U.ON. , cilt.26, sa.5, ss.2026-2032, 2021 (SCI-Expanded, Scopus)

26. Recovery of Symmetrical Peripheral Gangrene of Limbs in a Patient After Performing Hemoadsorption in Septic Shock

Uncu Ulu B., YİĞENOĞLU T. N., Hacıbekiroğlu T., Sağlam D. A., Kılınç A., İSKENDER G., et al.

Journal of Clinical Apheresis , cilt.36, sa.4, ss.649-653, 2021 (SCI-Expanded, Scopus)

27. Pralatrexate experience in peripheral T-cell lymphoma: A multicenter retrospective study from Turkey

DAL M. S., Merdin A., ERKURT M. A., Ekinci Ö., ALBAYRAK M., Hacıoglu S. K., et al.

Journal of B.U.ON. , cilt.26, sa.4, ss.1536-1539, 2021 (SCI-Expanded, Scopus)

28. The effect of bulky mass on prognosis in diffuse large-B-cell lymphoma: still poor?

BAŞCI S., YİĞENOĞLU T. N., Bakırtaş M., Uncu Ulu B., Yaman S., DAL M. S., et al.

Leukemia Research , cilt.102, 2021 (SCI-Expanded, Scopus)

29. Evaluation of risk factors and causative pathogens in bloodstream infections in cancer patients

Mert O. D., Merdin A., Kandemir N., KIZIL ÇAKAR M., Dirim E., ÇEKEN S., et al.

Gulhane Medical Journal , cilt.63, sa.1, ss.42-51, 2021 (Scopus, TRDizin)

30. Old is bad? The effect of age on peripheral stem cell mobilization and transplantation outcomes

BAŞCI S., Bakırtaş M., Uncu Ulu B., YİĞENOĞLU T. N., Yaman S., BATGİ H., et al.

Transfusion and Apheresis Science , cilt.60, sa.1, 2021 (SCI-Expanded, Scopus)

31. Is classical Hodgkin lymphoma a different disease in the elderly? A single-center retrospective cohort study

YILDIZ J., Ulu B., YİĞENOĞLU T. N., BAŞCI S., Darçin T., Bakirtaş M., et al.

European Review for Medical and Pharmacological Sciences , cilt.25, sa.10, ss.3655-3660, 2021 (SCI-Expanded, Scopus)

32. The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience

BATGİ H., Merdin A., DAL M. S., KIZIL ÇAKAR M., YILDIZ J., BAŞCI S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.8, ss.1857-1863, 2020 (SCI-Expanded, Scopus)

33. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Bekoz H., Ozbalak M., KARADURMUŞ N., PAYDAŞ S., Turker A., TOPTAŞ T., et al.

Annals of Hematology , cilt.99, sa.11, ss.2565-2576, 2020 (SCI-Expanded, Scopus)

34. A multiple myeloma patient who developed ischemic colitis during lenalidomide treatment: A rare case report

BATGİ H., DAL M. S., Merdin A., KIZIL ÇAKAR M., YİĞENOĞLU T. N., ALTUNTAŞ F.

Journal of Oncology Pharmacy Practice , cilt.26, sa.6, ss.1499-1500, 2020 (SCI-Expanded, Scopus)

35. Evaluation of HBV, HCV, and HIV seroprevalence in patients with plasma cell disorders

MERT D., Merdin A., KIZIL ÇAKAR M., DAL M. S., ALTUNTAŞ F.

Medicine (United States) , cilt.99, sa.34, 2020 (SCI-Expanded, Scopus)

36. Inferior prognosis in poor mobilizing myeloma patients

YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Bakırtaş M., Kılınç A., Şahin D., et al.

Transfusion and Apheresis Science , cilt.59, sa.3, 2020 (SCI-Expanded, Scopus)

37. Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor

Merdin A., KIZIL ÇAKAR M., DAL M. S., MERT D., YILDIZ J., BAŞCI S., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.4, ss.929-932, 2020 (SCI-Expanded, Scopus)

38. The effect of serum vitamin B12, folate, ferritin levels and transferrin saturation on stem cell mobilization in allogeneic donors

YİĞENOĞLU T. N., BAŞCI S., Bakırtaş M., Ulu B. U., Kılınç A., Şahin D., et al.

Transfusion and Apheresis Science , cilt.59, sa.3, 2020 (SCI-Expanded, Scopus)

39. The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma

KIZIL ÇAKAR M., Tekgündüz E., Dal M. S., Merdin A., BAŞCI S., Uğur B., et al.

Journal of Oncology Pharmacy Practice , cilt.26, sa.2, ss.273-278, 2020 (SCI-Expanded, Scopus)

40. Evaluation of clinical outcome and mixed chimerism follow-up after allogeneic hematopoietic stem cell transplantation in hematological malignancies

Bahsi T., YİĞENOĞLU T. N., ERDEM H. B., KIZIL ÇAKAR M., DAL M. S., ALTUNTAŞ F.

Gazi Medical Journal , cilt.31, sa.1, ss.52-55, 2020 (ESCI, Scopus)

41. Analysis of pre-chemotherapy WBC, PLT, monocyte, hemoglobin, and MPV levels in acute myeloid leukemia patients with WT1, FLT3, or NPM gene mutations

Merdin A., DAL M. S., KIZIL ÇAKAR M., YILDIZ J., Ulu B. U., BATGİ H., et al.

Medicine (United States) , cilt.99, sa.14, 2020 (SCI-Expanded, Scopus)

42. The Outcome of Autologous Stem Cell Transplantation in Adolescent and Young Adult Patients with Multiple Myeloma

YİĞENOĞLU T. N., BAŞCI S., Ulu B. U., Bakirtas M., Sahin D., Darcin T., et al.

Eurasian Journal of Medicine and Oncology , cilt.4, sa.1, ss.79-83, 2020 (ESCI, Scopus, TRDizin)

43. Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia

NAMDAROĞLU S., Kaya A. H., BATGİ H., Kayikci O., DAL M. S., İSKENDER D., et al.

Scientific Reports , cilt.9, sa.1, 2019 (SCI-Expanded, Scopus)

44. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment

Merdin A., İSKENDER D., Ulu B. U., Doğan M., KIZIL ÇAKAR M., DAL M. S., et al.

Medicine , cilt.98, sa.30, 2019 (SCI-Expanded, Scopus)

45. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy

Kaya A. H., Tekgündüz E., İLKKILIÇ K., Dal M. S., Merdin A., Karakus A., et al.

Journal of Chemotherapy , cilt.30, sa.1, ss.44-48, 2018 (SCI-Expanded, Scopus)

Yayınlar & Eserler

Yayın

Yayın (WoS)

Yayın (Scopus)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Proje

Tez Danışmanlığı

Açık Erişim